Author | OTE Staff Reports


High dose aflibercept shows improvement for wet AMD patients in CANDELA

At Angiogenesis, Dr David Brown presented the Phase 2 results of the CANDELA study for high dose aflibercept 8 milligram for wet AMD; here, he discusses those results.

Leveraging deep learning for diabetic retinopathy detection with ultra-wide field imaging

During her talk at Angiogenesis, Dr Anat Loewenstein outlines how artificial intelligence could revolutionize diabetic retinopathy screening.

Exploring the link between choriocapillaris, atrophy and neovascular AMD

At Angiogenesis, Dr SriniVas R. Sadda discusses how choriocapillaris may predict the rate of progression of atrophy.